Golden
Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics is a poseida Therapeutics develops targeted cell therapy.

Poseida Therapeutics is a privately held, biopharmaceutical company based in San Diego California. It leverages proprietary non-viral, gene engineering technologies to create therapeutics for illnesses with high unmet medical needs. The company is developing a wholly-owned pipeline of autologous and allogenic CAR-T product candidates, initially focused on the treatment of hematological malignancies and other solid tumors.



Poseida's leading product candidate is P-BCMA-101, an autologous CAR-T product that targets B cell maturation antigen, or BCMA, which is expressed on multiple myeloma cells. In December 2018, the company announced positive results from its first cohort of ongoing Phase 1 clinical trial. Poseida's second autologous product is P-PSMA-101, targeting cells that express prostate-specific membrane antigen, which is expressed on most prostate cancer cells. The product is being developed to treat patients with castrate-resistance prostate cancer, or CRPC, a solid tumor indication, with Phase 1 clinical trials planned in the second half of 2019.



Under the allogenic category, Poseida has P-BCMA-ALL01 and P-MUC1C-101. Derived from healthy donors, P-BCMA-ALL01 is designed to have the same inherent properties and functions of P-BCMA-101, but with the benefits of scale and administration efficiency that come from an allogenic product. The company plans to file an IND and begin Phase 1 clinical trials by late 2019 or early 2020. As for P-MUC1C-101, the product is in late-stage pre-clinical development for multiple solid tumor indications with plans for Phase 1 clinical trials in 2020.



In January 2019, Poseida Therapeutics filed documents for an IPO of $115 million.

Timeline

People

Name
Role
LinkedIn

Debra Gessner

VP, Regulatory Affairs



Devon J. Shedlock

VP, Preclinical Development



Eric Ostertag

CEO



Glenn Dourado

VP, Business Development



Jeff Knight

VP, Clinical Development Operations and Project Management



Jennifer Collins

VP, Quality Operations



Johanna Mylet

VP, Finance



Marcy Graham

VP, Corporate Affairs



Mark J. Gergen

Chief Business Officer and Chief Financial Officer



Martin Giedlin

VP, Technical Operations



Matthew A. Spear

Chief Medical Officer



Paiman Peter Ghoroghchian

Chief Technical Officer



Further reading

Title
Author
Link
Type
Date

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Poseida Therapeutics, Inc.

Web



Xconomy: Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments



Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References